CA Patent

CA2532804A1 — Substituted 2-aminotetralin for the treatment of depression

Assigned to UCB Pharma GmbH · Expires 2005-02-03 · 21y expired

What this patent protects

The invention relates to the use of a compound of general formula (I) and the pharmaceutically acceptable salts, racemates or pure entiomers thereof for the production of a medicament used to treat depression. The substituents are defined as in the description.

USPTO Abstract

The invention relates to the use of a compound of general formula (I) and the pharmaceutically acceptable salts, racemates or pure entiomers thereof for the production of a medicament used to treat depression. The substituents are defined as in the description.

Drugs covered by this patent

Patent Metadata

Patent number
CA2532804A1
Jurisdiction
CA
Classification
—
Expires
2005-02-03
Drug substance claim
No
Drug product claim
No
Assignee
UCB Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.